A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Type 2 Diabetes Mellitus, HbA1c, Sulfonylurea, Topiramate, Adult-Onset Diabetes Mellitus (AODM)
Eligibility Criteria
Inclusion Criteria: Diagnosis of Type 2 Diabetes, receiving only second generation sulfonylurea therapy (may include: glipizide, gliclazide, glimepiride, glibenclamide/glyburide, and gliquadone) for at least 4 months and on stable dose for at least 2 months Body Mass Index >= 27 and < 50 HbA1c < 11% at enrollment Diagnosed hypertension or hyperlipidemia must be controlled Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test) Exclusion Criteria: Known contraindication or hypersensitivity to topiramate or sulfonylurea therapy Pregnancy or women who are nursing or plan to become pregnant during the study Diagnosed with Type 1 diabetes History of severe or recurrent hypoglycemic episodes Treatment with any antidiabetic agent other than sulfonylurea